Wall Street’s IPO pipeline is facing a rougher third quarter, with postponements and withdrawals multiplying across several industries. Biometric ring maker Oura became the latest prominent company to step back Tuesday, delaying its initial public offering while citing “uncertainty” in market conditions and claiming “strong demand” for its stock.
Oura faced concerns particular to its concentrated product lineup, but analysts said the broader pattern cannot be dismissed as a collection of isolated corporate problems. Rising bond yields and other market pressures are becoming obstacles for businesses considering public offerings.
“The fact that we’ve had three or four in a row – a string of postponements – I think that does tell you something about the market,” Matthew Kennedy, senior strategist at IPO specialist Renaissance Capital, told CNBC. “You can’t really point to all four of them and say it’s company-specific issues.”
Four companies from different sectors, each seeking to raise at least $50 million, postponed or withdrew IPOs during the past week, according to Renaissance Capital data. The quarterly total has now reached seven, compared with four during the second quarter and three during the first.
Before Oura announced its postponement Tuesday, nuclear power component maker Holtec Nuclear withdrew its IPO last Friday. Materials company Amaero postponed its offering last Wednesday, while Bamboo Insurance postponed its IPO on Sept. 22.
“I’ve got a little bit of sympathy for market conditions as a rationale,” said Jay Ritter, director of the IPO Initiative at the University of Florida’s Warrington College of Business. “The fact that three prominent companies are doing this does indicate that it’s not company-specific.”
The recent delays follow what has otherwise been a solid year for IPO fundraising. About $146.9 billion in proceeds has come from 110 deals, excluding special purpose acquisition companies, according to Renaissance Capital.
The annual figures include major second quarter offerings from SpaceX and South Korean memory maker SK Hynix. Even so, the number of deals is down 30% from the same point last year.
There were 202 IPOs during all of 2025, the highest annual total since 2021, when the market recorded close to 400. Total proceeds have risen 394% this year, driven largely by offerings from SpaceX, SK Hynix and Cerebras.
Health care and industrial companies are tied as the leading sectors for IPO launches through the year to date, with each representing 24% of the total. Technology ranks third and accounts for 18%.
Among all 2026 offerings, 59% are trading at or above their IPO prices. Notably, the three prominent offerings from SpaceX, SK Hynix and Cerebras are lagging.
Macroeconomic pressures and concerns about the artificial intelligence expansion have recently weighed on the market for new offerings. The Renaissance IPO ETF reached its peak in June, when SpaceX launched.
“IPO activity came in below expectations in the third quarter of 2026, as more concerns about AI spending, a 19-year high in bond yields and resumed rate hikes weighed on the fall pickup,” Renaissance analysts wrote in a report to clients last week.
Ritter said enthusiasm remains for artificial intelligence projects, including the construction of major infrastructure. “AI-related stuff, including the build-out of the big infrastructure, still has a lot of enthusiasm for it. Things like data centers, there’s big demand there, but it’s largely a commodity business,” he said.
Oura may also have encountered skepticism tied directly to its heavy reliance on a single type of consumer device. Gil Luria, head of technology research at DA Davidson, compared the company with Peloton, GoPro and FitBit, saying investors have suffered significant losses from narrow consumer product businesses.
“I would draw a line [around] Peloton , GoPro , FitBit and Oura. Investors have been burned pretty badly by narrow consumer products, and that is the reaction Oura is getting,” Luria said. “I don’t think it has to do with tech or tech allocation, I think it has to do with a narrow consumer product.”
Companies also have more options for raising money privately, reducing the pressure to accept public market valuations they consider inadequate. Lawyers specializing in public markets said private capital has become a more substantial alternative.
“The depth of private capital and alternatives is enormous now, and much more complex and diverse,” said Ian Schuman, chair of capital markets and public company representation practices at Latham and Watkins. “You don’t necessarily, absolutely need to tap the public markets, if you’re not getting the value you want.”